View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 17, 2022

WHO recommends GSK-Vir and Lilly’s drugs for Covid-19 treatment

GSK-Vir’s sotrovimab was demonstrated to retain activity against Omicron variant in initial laboratory studies.

The World Health Organization (WHO) has recommended the use of two new drugs by GlaxoSmithKline (GSK) and Vir Biotechnology and Eli Lilly to treat Covid-19.

The latest advice offers additional options to treat the infection. 

Lilly’s baricitinib is strongly advised for use in severe or critical Covid-19 patients administered along with corticosteroids.

Discovered by Incyte and licensed to Lilly, the oral drug belongs to a class of therapeutics called Janus kinase (JAK) inhibitors used for preventing immune system overstimulation. 

It is also used for treating rheumatoid arthritis and offers a substitute to existing arthritis therapies known as interleukin-6 receptor inhibitors, which the WHO had recommended in July last year.

Furthermore, WHO granted conditional recommendation for GSK-Vir’s monoclonal antibody drug, sotrovimab, to treat individuals with mild or moderate Covid-19 who are at increased hospital admission risk. 

The patient population includes the older, immunocompromised people with underlying conditions such as hypertension, diabetes and obesity and those who have not received Covid-19 vaccines.

Sotrovimab is a substitute to a cocktail of monoclonal antibodies, casirivimab and imdevimab, recommended by WHO in September last year. 

Studies are underway to analyse the monoclonal antibodies against the Omicron variant of the SARS-CoV-2 virus but in initial laboratory studies, sotrovimab was demonstrated to retain activity.

Baricitinib and sotrovimab are invited for WHO Prequalification, which evaluates the efficacy, quality and safety of priority health products to boost access in lower-income nations. 

The expert panel developing the guidelines also analysed two other therapies, ruxolitinib and tofacitinib, to treat severe and critical Covid-19. 

Due to uncertainty in effects, WHO issued a conditional recommendation against their usage.

The latest recommendations that form the eighth update to WHO guidelines on Covid-19 therapies are based on data obtained from seven clinical trials that enrolled more than 4,000 non-severe, severe and critical Covid-19 patients.

WHO is holding talks with manufacturers to ensure international supply capacity and equal access to the newly recommended therapies. 

The Access to Covid-19 Tools Accelerator (ACT-A) Therapeutics pillar has been working with pharmaceutical firms for complete comprehensive access strategies for low and middle-income nations, facilitating the quick deployment of the therapies. 

Furthermore, the ACT-A is exploring options to extend the licencing scope in order to make the therapeutics inexpensive.

In December last year, Novavax and Serum Institute of India (SII) obtained WHO Emergency Use Listing for the former’s Covid-19 vaccine with Matrix-M adjuvant, NVX-CoV2373.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU